N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells
© Kretzmann et al.; licensee BioMed Central Ltd. 2012
Received: 29 November 2011
Accepted: 27 November 2012
Published: 4 December 2012
Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC.
NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB.
Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment.
Hepatocarcinoma (HCC) is the most common primary malignancy of the liver, typically observed as a complication of chronic liver disease. It is the fifth most common tumour worldwide, with more than 700,000 new cases per year . Cirrhosis of different etiologies such as alcohol, primary biliary cirrhosis, or chronic infection with hepatitis B or C (HBV, HCV) are risk factors that predispose patients to HCC . The development of HCC is a complex process, with the accumulation of genetic and epigenetic alterations, which pass through the events of tumour initiation, promotion and progression [2–4].
HCV chronic infection can induce chaotic cellular signalling, raising tumour cells with activation of epidermal growth factor (EGF)  and NF-kB, contributing to tumour development and survival of infected cells . Interferon (IFN) is the most used drug in chronic hepatitis and HCC due to its properties of immune response activation and also regulation of differentiation and cell growth. IFN has also shown satisfactory results mainly in treating hematologic malignancies and Kaposi’s Sarcoma, among other diseases . In HCC, studies have shown that IFN does not decrease metastasis or recurrence .
Other studies have shown that the progression of HCC is accompanied by activation of nuclear factor-kappa B (NF-kB) [6, 9]. NF-kB is a transcription factor that plays an important and decisive role both in normal situations and in the coordination of adaptive immune responses, regulating the expression of many cellular mediators . The family of NF-kB/Rel comprises five subunits, called p50, p52, p65 (RelA), c-Rel, and RelB. The activation of NF-kB requires the phosphorylation of its physiological inhibitors (particularly IkBα) in serine specific sites (Ser-32 and Ser-36), a process mediated by the complex inhibitor kappa kinases (IKKs) . One of the documented functions of NF-kB is its ability to promote cellular survival due to induction of specific genes that inhibit apoptotic machinery in both normal and malignant cells [11, 12]. NF-kB also prevents necrosis by inducing genes encoding antioxidant proteins [12–14]. Since NF-kB is a usual pathway that promotes resistance to drugs and radiation by tumoural cells, inhibition of NF-kB seems to be promising in improving the efficacy of conventional anti-cancer therapies [15, 16].
NF-kB is also directly involved in oxidative stress and inflammation [12, 17]. N-acetylcysteine (NAC) is one of the most used antioxidant drugs in liver diseases [18, 19] and is known to be able to increase the levels of glutathione and also act as a free radical scavenger. Cell culture and animal studies have shown that NAC can protect normal cells, but not malignant cells, from the toxic effects of radiotherapy and chemotherapy . The administration of NAC may have a role in cancer prevention and even in the treatment of some forms of cancer, as DNA induced damage can be completely blocked by NAC [21, 22]. We herein tested the antitumoural effect of NAC on HCC cells and its relationship with the NF-kB pathway.
Cell culture and treatment
Human HepG2 and Huh7 HCC cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Stock cells were routinely grown as monolayer cultures in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% foetal bovine serum, penicillin (100 U/mL), streptomycin (100 mg/mL), glutamine (4 mM), and pyruvate (100 mg/mL) in a humidified 5% CO2 atmosphere at 37°C and the medium was changed every other day. Cells were maintained in T75 culture flasks and subcultured once a week in a total volume of 10 mL of complete medium. Cell culture reagents were purchased from Gibco (Invitrogen, Carlsbad, CA, USA), and culture flasks and dishes were purchased from TPP (Techno Plastic Products, Switzerland).
Twenty-four hours before treatments, 105 HepG2 and Huh7 cells were replated in 6-well plates containing IFN-α 2A (Blausiegel Ind Ltda, SP-Brazil) at concentrations ranging from 0 to 105 IU/mL and NAC (Sigma, Brazil) at final concentrations of 5, 10 and 20 mM. Both drugs were first diluted in PBS and then in DMEM to the final concentrations. Commercial p65 siRNA (250 mM) (Cell Signaling Biotechnology, Danvers, MA, USA) was used to suppress the NF-kB pathway, as described below. Cells were harvested after 24, 48, 72 and 96 h of treatment. Untreated cells used as controls (CO) were incubated in standard conditions. All experiments were performed in triplicate.
Cell viability assay
For the cell viability assay 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, Sigma, Brazil) and confluent HepG2 and Huh7 cells were replated in 96-well culture plates, at a density of 3 x 103 cells/well, in a total volume of 200 μL of complete medium.
The MTT assay was carried out as described by Denizot and Lang . Briefly, after exposure of cells to IFN-α, NAC, NAC plus IFN-α, or siRNA (p65 or control) culture media was changed to serum-free media containing dissolved MTT (5 mg/mL). After 4 h, serum-free culture media containing MTT was discarded and DMSO was added to each well to dissolve the precipitate. The optical density was measured at 492 nm using a microtiter plate reader (Zenyth 200rt Microplate Reader; Anthos, Austria).
Apoptosis analysis: Flow Cytometry and Fluorescent microscopy
Apoptosis was assessed using annexin-V conjugated with FITC (fluorescein isothiocyanate). HepG2 and Huh7 were treated with IFN-α, NAC or NAC plus IFN-α for 24, 48 or 72 h, as indicated. After treatment, cells were washed twice with PBS, and stained with PI and FITC-annexin–V (Apoptosis & Necrosis Quantification Kit, Biotium Hayward; CA USA) for 15 min in the dark. Cells were immediately analysed on GUAVA flow cytometer for PI and FITC-annexin–V staining.
Apoptosis was also evaluated by examining Annexin–V FITC and PI staining under fluorescent microscopy. Briefly, HepG2 and Huh7 cells were replated in 96-well culture plates, at a density of 3 x 103 cells/well. Then cells were treated with IFN-α, NAC or NAC plus IFN-α for 48 or 72 h. After treatment, cells were washed twice with PBS and stained with PI and annexin–V FITC (Apoptosis & Necrosis Quantification Kit, Biotium Hayward; CA USA) for 15 min in the dark. Cells were immediately analysed using the Olympus FluoView™ 1000 microscope (CME-UFRGS).
Western Blot Analysis
For western blot analysis of p65 expression, cell homogenates were prepared in 0.25 mM sucrose, 1 mM EDTA, 10 mM Tris and 1% protease inhibitor cocktail. The mixture was incubated for 30 min at 4°C and centrifuged for 30 min at 1,3000×g at 4°C. The supernatants were kept to analyse cell extracts. Samples containing 15 ug of protein were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (9% acrylamide) and transferred to a nitrocellulose membrane. Non-specific binding was blocked by preincubation in PBS containing 5% bovine serum albumin for 1 h. Membranes were then incubated overnight at 4°C with polyclonal anti-p65 (65 kDa) (Cell Signaling Technology, Danvers, MA) and anti-β-actin (42 kDa) (Sigma Brazil), prepared as described by Guitierrez . Bound primary antibody was detected by incubation with HRP-conjugated anti-rabbit antibody for 2 h (DAKO, Glostrup, Denmark) and bands were revealed using an enhanced chemiluminescence detection system (ECL kit, (GE Healthcare, Piscataway, NJ, USA). The densities of the specific bands were quantified with an imaging densitometer (Scion Image, Maryland, MA) .
Silencing of p65 expression with siRNA
Briefly, HepG2 and Huh7 cells were replated in 12-well plates at 104 cells/well 24 hours after culture media was changed to serum-free media. Cells were then washed twice with PBS before transfection. Specific predesigned small interfering RNAs (siRNA) to p65 were ordered from Cell Signaling Biotechnology (CA, USA) and transfected into HepG2 and Huh7 cells with the accompanying transfection reagent according to the manufacturer’s instructions. siRNA with equivalent %GC nucleotide content and FITC labelling was used as a control. Cells were assayed 24 h after siRNA duplex transfection. The effect of p65 suppression was monitored by p65 mRNA levels.
RNA isolation and Real-Time PCR
Total RNA from cells subjected to different treatments was extracted using the RNeasy Mini Kit (Qiagen, Germany). RNA was quantified and the quality tested by photometric measurement on a Nanodrop apparatus (Wilmington, DE, USA). Only highly purified RNA (A260/A280>1.95) was used. cDNA synthesis was performed using the SuperScript™ III/RNaseOUT™ Enzyme Mix 2 and 50 μM oligo(dT) random primers (Invitrogen, Carlsbad, CA, USA). The cDNA was stored at −20°C.
Oligonucleotide primers for the amplification were obtained from the Harvard Medical School Primer Bank (http://pga.mgh.harvard.edu/primerbank/). The primer sequences used were as follows: p65 Forward Primer 5′-TTGAGGTGTATTTCACGGGACC-3′ and Reverse Primer 5′-GCACATCAGCTTGCGAAAAGG-3′, and GAPDH Forward Primer 5′-CCCATCACCATCTTCCAGG-3′ and Reverse Primer 5′-GAGATGATGACCCTTTTGGC-3′). PCRs were carried out in a final volume of 25 μl, containing 1 μM of both primers, 1x SYBR Green Supermix (Applied Biosystems), and variable amounts of cDNA templates. The program profile used for p65 amplification was the following: 95°C for 2 min, 45 cycles of denaturation for 30 sec at 95°C, annealing for 15 sec at 52°C and extension for 30 sec at 60°C. The program profile used for GAPDH was 95°C for 2 min followed by 45 cycles of denaturation, annealing and extension for 30 sec each at 95°C, 65°C and 60°C, respectively [26, 27]. Thermal cycling was performed in a Mx3000P™ real-time PCR system Stratagene Thermocycler (GE, USA). Data were analysed with the accompanying software MX PRO System Software, using 2ΔΔCt formula.
Means and standard errors of the mean (SEM) were calculated. Significant differences between means were evaluated by analyses of variance and in the case of significance; a Newman–Keul’s post-hoc test was also applied. Real-time PCR data was analysed by a Student’s t-test. A difference was considered significant when P was less than 0.05. SPSS+ version 13.0 statistical software was used.
NAC and IFN-a decrease cell viability of liver cancer cells
Inhibition of NF-kB pathway by NAC induces apoptosis in HCC cells
NAC increases IFN-a antitumoural responses mediated by NF-kB Pathway inhibition
Given that the efficiency of IFN-α is only marginal in treating HCC, our study aimed to evaluate the effect of NAC on IFN-α toxicity, and how the co-treatment of NAC and IFN-α modulates cell death and growth inhibition in HCC human cell lines. We showed that NAC decreased cell viability through downregulation of the NF-kB pathway and induction of apoptosis. More importantly, NAC increased the toxicity of IFN-α through an additive induction of apoptosis and a synergistic decrease of NF-kB expression in HCC cells, pointing to different targets being modulated by IFN-α and NAC.
IFN-α has been shown to reduce the incidence of pre-neoplastic foci and cancer in liver cancer models [28, 29]. Our results in vitro using 2.5 x 104 U/mL showed a decrease in cell viability of around 30%, which could be considered a poor response. These results are in agreement with the poor response observed clinically, in which only around 30% of the patients respond to treatment . These data confirmed that development of alternative compounds to treat HCC, such as NAC tested here, is necessary.
The selective induction of apoptosis in cancer cells is an exciting possibility for the selective development of future therapies to treat HCC [31–33]. Knowing that one of the IFN-α mechanisms of action involves apoptosis through p53 induction and the activation of caspases [34–36], here we used cell lines with a different p53 status in order to establish the mechanisms involved in the toxicity of IFN-α and NAC in HCC cells. Some studies indicated that the presence of p53 would facilitate apoptosis induction [22, 37]. In our study we demonstrated that, despite leading to apoptosis in a p53-independent way, NAC triggered apoptosis in HepG2 p53 functional cells after 24 h of treatment, while in p53-deficient cells (Huh7) this effect was observed only after 48 hours of treatment. Furthermore, in HepG2 cells, NAC not only potentiated the effect of IFN-α in reducing cell viability, but also increased labelling with annexin V after 24 h without increasing the overall amount of apoptosis. More interestingly, after 48 h and 72 h of treatment with NAC, we did not observe any more annexin-positive cells in the HepG2 cells, while in IFN-α and NAC plus IFN-α treatments, we still observed annexin-positive cells after 48 h and 72 h. This suggests that NAC triggered apoptosis in some of the HepG2 cells, and those that remained were resistant to treatment, while co-treatment surpassed this resistance. This finding is an important point to be considered in clinical approaches using NAC or co-treatment with IFN-α.
High expression of pro-angiogenic factors such as hypoxia-inducible factor-1α and cell growth/survival factors such as CD24 and activation of inflammatory signalling pathways such as Wnt/β-catenin, nuclear factor-kappa B and signal transducer and activator of transcription 3 predict early recurrence of HCC [4, 38]. Wnt/B-Catenin signaling is one of many pathways that are also altered in HCC, but it is also known that it responds to both NAC and INF used alone. It is conceivable that the use of both drugs could also have a synergistic effect on this pathway as well [39–41]. p53 and other transcription factors have been closely linked to cancer and related therapies. Data suggest that IkB simultaneously downregulates NF-kB activation and sequesters p53 in the cytoplasm, thus enhancing NF-kB-regulated apoptosis but blocking p53-dependent apoptosis . It is thought that several carcinogens and tumour promoters act through the constitutive activation of NF-kB [16, 43], which induces the resistance of cancer cells to chemotherapeutic agents and radiation . The balance between proliferation and cell death is a decisive factor in the progression or inhibition of carcinogenesis, and a variety of mechanisms can be activated or inactivated to induce apoptosis . Antioxidant molecules that have a thiol group, such as NAC, have the ability to promote several of these mechanisms in different types of human tumours [13, 45]. One of these mechanisms refers to upregulation of pro-apoptotic genes together with the downregulation of inhibitors of apoptosis genes, often accompanied by increased permeability of the mitochondrial membrane and release of cytochrome c, activating the caspase cascade. And all of these events are regulated by activation or inactivation of NF-kB [24, 46, 47]. Data from the present study confirm the findings of previous studies that showed a decrease in the expression of the p65 subunit using NAC or IFN-α [31, 48–53]. More importantly, combined treatment further reduced levels of p65 in a synergistic way, again suggesting that NAC and IFN-α act in different pathways. Since several genes involved in the initiation, promotion and tumour progression are regulated by NF-kB and its activation suppresses apoptosis and promotes cell proliferation [16, 54], the rational design of treatments that decrease NF-kB activity is a good strategy to treat malignancies, as observed here.
Confirming the involvement of NF-kB on the effect of NAC, we found that cells transfected with siRNA for the p65 (KD cells) had the same response of cells treated only with NAC. Furthermore, KD cells treated with IFN-α had the same response as the combined treatment with NAC plus IFN-α while knockdown of NF-kB did not alter the sensitivity to NAC. Altogether, these data suggest that the increase in growth inhibition shown by NAC is probably due to the inhibition of NF-kB pathway. Even though it has been shown that IFN-α may have a role in blocking the NF-kB activating pathway triggered by the hepatitis B virus , this was not observed in our experiments. IFN-α treatment alone showed only a slight decrease in NF-kB activation, suggesting that IFN-α may act through different mechanisms depending on cell type and context.
In conclusion, NAC potentiates the antitumoural effect of IFN-α, decreasing cell viability, increasing apoptosis and decreasing the expression of the p65 subunit of NF-kB. Considering that NF-kB is a molecule of great importance in the initiation, promotion and progression of tumours and that NAC acts on the inactivation of this pathway with a tumoural-specific toxicity, we suggest that NAC is a promising agent for use in HCC, primarily or as an adjuvant with IFN-α.
We thank CME-UFRGS for confocal microscopy supply. This work was supported by CAPES-BRASIL/ESPANHA, FIPE-HCPA, UFCSPA.
- Pache I, Bize P, Halkic N, Montemurro M, Giostra E, Majno P, Moradpour D: [Management of hepatocellular carcinoma]. Rev Med Suisse. 2010, 6: 198-202.PubMedGoogle Scholar
- Cervello M, Montalto G: Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol. 2006, 12: 5113-5121.PubMed CentralPubMedGoogle Scholar
- Jain S, Singhal S, Lee P, Xu R: Molecular genetics of hepatocellular neoplasia. Am J Transl Res. 2010, 2: 105-118.PubMed CentralPubMedGoogle Scholar
- Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet J: Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Semin Liver Dis. 2010, 30: 35-51. 10.1055/s-0030-1247131.PubMed CentralView ArticlePubMedGoogle Scholar
- El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N: Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS. 2006, 114: 420-427. 10.1111/j.1600-0463.2006.apm_323.x.View ArticlePubMedGoogle Scholar
- Nguyen H, Sankaran S, Dandekar S: Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology. 2006, 354: 58-68. 10.1016/j.virol.2006.04.028.View ArticlePubMedGoogle Scholar
- Goldstein D, Laszlo J: The role of interferon in cancer therapy: a current perspective. CA Cancer J Clin. 1988, 38: 258-277. 10.3322/canjclin.38.5.258.View ArticlePubMedGoogle Scholar
- Zhuang P, Zhang J, Zhang W, Zhu X, Liang Y, Xu H, Xiong Y, Kong L, Wang L, Wu W, Tang Z, Qin L, Sun H: Long-term interferon-alpha treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010, 136: 1891-1900. 10.1007/s00432-010-0848-1.View ArticlePubMedGoogle Scholar
- Guo L, Guo Y, Xiao S: Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology. 2007, 72: 410-416. 10.1159/000113491.View ArticlePubMedGoogle Scholar
- Zingarelli B, Sheehan M, Wong HR: Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med. 2003, 31: S105-S111. 10.1097/00003246-200301001-00015.View ArticlePubMedGoogle Scholar
- Dutta J, Fan Y, Gupta N, Fan G, Gélinas C: Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006, 25: 6800-6816. 10.1038/sj.onc.1209938.View ArticlePubMedGoogle Scholar
- Tas S, Vervoordeldonk M, Tak P: Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther. 2009, 9: 160-170. 10.2174/156652309788488569.PubMed CentralView ArticlePubMedGoogle Scholar
- Duan W, Jin X, Li Q, Tashiro S, Onodera S, Ikejima T: Silibinin induced autophagic and apoptotic cell death in HT1080 cells through a reactive oxygen species pathway. J Pharmacol Sci. 2010, 113: 48-56. 10.1254/jphs.09315FP.View ArticlePubMedGoogle Scholar
- Luo J, Kamata H, Karin M: The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol. 2005, 25: 541-550. 10.1007/s10875-005-8217-6.View ArticlePubMedGoogle Scholar
- Nakanishi C, Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005, 5: 297-309. 10.1038/nrc1588.View ArticlePubMedGoogle Scholar
- Lin Y, Bai L, Chen W, Xu S: The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010, 14: 45-55. 10.1517/14728220903431069.PubMed CentralView ArticlePubMedGoogle Scholar
- Fillmann H, Kretzmann N, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, Tuñón M: Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology. 2007, 236: 217-226. 10.1016/j.tox.2007.04.012.View ArticlePubMedGoogle Scholar
- Millea P: N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009, 80: 265-269.PubMedGoogle Scholar
- Moreno-Otero R, Trapero-Marugán M: Hepatoprotective effects of antioxidants in chronic hepatitis C. World J Gastroenterol. 2010, 16: 1937-1938. 10.3748/wjg.v16.i15.1937.PubMed CentralView ArticlePubMedGoogle Scholar
- Wanamarta A, van Rijn J, Blank L, Haveman J, van Zandwijk N, Joenje H: Effect of N-acetylcysteine on the antiproliferative action of X-rays or bleomycin in cultured human lung tumor cells. J Cancer Res Clin Oncol. 1989, 115: 340-344. 10.1007/BF00400960.View ArticlePubMedGoogle Scholar
- Morley N, Curnow A, Salter L, Campbell S, Gould D: N-acetyl-L-cysteine prevents DNA damage induced by UVA, UVB and visible radiation in human fibroblasts. J Photochem Photobiol B. 2003, 72: 55-60. 10.1016/j.jphotobiol.2003.06.004.View ArticlePubMedGoogle Scholar
- De Flora S, D’Agostini F, Masiello L, Giunciuglio D, Albini A: Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int J Cancer. 1996, 67: 842-848. 10.1002/(SICI)1097-0215(19960917)67:6<842::AID-IJC14>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986, 89: 271-277.PubMedGoogle Scholar
- Gutierrez MB, Miguel BS, Villares C, Gallego JG, Tunon MJ: Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-kappaB activation or iNOS expression. Toxicology. 2006, 222: 125-131. 10.1016/j.tox.2006.02.002.View ArticlePubMedGoogle Scholar
- Brasil LJ, San-Miguel B, Kretzmann NA, Amaral JL, Zettler CG, Marroni N, Gonzalez-Gallego J, Tunon MJ: Halothane induces oxidative stress and NF-kappaB activation in rat liver: protective effect of propofol. Toxicology. 2006, 227: 53-61. 10.1016/j.tox.2006.07.013.View ArticlePubMedGoogle Scholar
- Tichopad A, Bar T, Pecen L, Kitchen R, Kubista M, Pfaffl M: Quality control for quantitative PCR based on amplification compatibility test. Methods. 2010, 50: 308-312. 10.1016/j.ymeth.2010.01.028.View ArticlePubMedGoogle Scholar
- Pfaffl M: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29: e45-10.1093/nar/29.9.e45.PubMed CentralView ArticlePubMedGoogle Scholar
- Yano H: Inhibitory function of interferon on hepatocarcinogenesis. Oncology. 2008, 75 (Suppl 1): 22-29.View ArticlePubMedGoogle Scholar
- Yano H, Basaki Y, Oie S, Ogasawara S, Momosaki S, Akiba J, Nishida N, Kojiro S, Ishizaki H, Moriya F, et al: Effects of IFN-alpha on alpha-fetoprotein expressions in hepatocellular carcinoma cells. J Interferon Cytokine Res. 2007, 27: 231-238. 10.1089/jir.2006.0135.View ArticlePubMedGoogle Scholar
- Caglar M, Sari O, Akcan Y: Prediction of therapy response to interferon-alpha in chronic viral hepatitis-B by liver and hepatobiliary scintigraphy. Ann Nucl Med. 2002, 16: 511-514. 10.1007/BF02988654.View ArticlePubMedGoogle Scholar
- Guan D, Xu Y, Yang M, Wang H, Wang X, Shen Z: N-acetyl cysteine and penicillamine induce apoptosis via the ER stress response-signaling pathway. Mol Carcinog. 2010, 49: 68-74.PubMedGoogle Scholar
- Herzer K, Hofmann T, Teufel A, Schimanski C, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle P: IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009, 69: 855-862. 10.1158/0008-5472.CAN-08-2831.View ArticlePubMedGoogle Scholar
- Lim dY, Jeong Y, Tyner A, Park J: Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol. 2007, 292: G66-G75.View ArticleGoogle Scholar
- Bekisz J, Baron S, Balinsky C, Morrow A, Zoon K: Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel). 2010, 3: 994-1015.View ArticleGoogle Scholar
- Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park A, Munakata H: The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol. 2010, 46: 212-221.View ArticlePubMedGoogle Scholar
- Su W, Liu W, Cheng C, Chou Y, Hung K, Huang W, Wu C, Li Y, Shiau A, Lai M: Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett. 2009, 583: 2793-2798. 10.1016/j.febslet.2009.07.027.View ArticlePubMedGoogle Scholar
- García A, Morales P, Rafter J, Haza A: N-Nitrosopiperidine and N-Nitrosodibutylamine induce apoptosis in HepG2 cells via the caspase dependent pathway. Cell Biol Int. 2009, 33: 1280-1286. 10.1016/j.cellbi.2009.08.015.View ArticlePubMedGoogle Scholar
- Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012, -Google Scholar
- Ceballos MP, Parody JP, Alvarez ML, Ingaramo PI, Carnovale CE, Carrillo MC: Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?. Biochem Pharmacol. 2011, 82: 1682-1691. 10.1016/j.bcp.2011.08.001.View ArticlePubMedGoogle Scholar
- Thompson MD, Dar MJ, Monga SP: Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin. J Hepatol. 2011, 54: 506-512. 10.1016/j.jhep.2010.07.020.PubMed CentralView ArticlePubMedGoogle Scholar
- North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W: PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci U S A. 2010, 107: 17315-17320. 10.1073/pnas.1008209107.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou M, Gu L, Zhu N, Woods W, Findley H: Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene. 2003, 22: 8137-8144. 10.1038/sj.onc.1206911.View ArticlePubMedGoogle Scholar
- Baud V, Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009, 8: 33-40. 10.1038/nrd2781.PubMed CentralView ArticlePubMedGoogle Scholar
- Jost P, Ruland J: Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007, 109: 2700-2707.PubMedGoogle Scholar
- Li J, Tu H, Dai G, Dai Y, Wu Q, Shi Q, Cao Q, Li Z: N-acetyl cysteine inhibits human signet ring cell gastric cancer cell line (SJ-89) cell growth by inducing apoptosis and DNA synthesis arrest. Eur J Gastroenterol Hepatol. 2007, 19: 769-774. 10.1097/MEG.0b013e3282202bda.View ArticlePubMedGoogle Scholar
- Kim K, Rhim T, Choi I, Kim S: N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem. 2001, 276: 40591-40598. 10.1074/jbc.M100975200.View ArticlePubMedGoogle Scholar
- Chen GQY, Yao J, Jiang Q, Lin X, Chen F, Lin F, Lin M, Lin L, Zhu P: Construction of NF-kappaB-targeting RNAi adenovirus vector and the effect of NF-kappaB pathway on proliferation and apoptosis of vascular endothelial cells. Mol Bio Rep. 2010, 38: 3089-3094.View ArticleGoogle Scholar
- Schubert S, Neeman I, Resnick N: A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J. 2002, 16: 1931-1933.PubMedGoogle Scholar
- Vercelino R, Crespo I, de Souza G, Cuevas M, de Oliveira M, Marroni N, González-Gallego J, Tuñón M: S-nitroso-N-acetylcysteine attenuates liver fibrosis in cirrhotic rats. J Mol Med. 2010, 88: 401-411. 10.1007/s00109-009-0577-6.View ArticlePubMedGoogle Scholar
- Havre P, O’Reilly S, McCormick J, Brash D: Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res. 2002, 62: 1443-1449.PubMedGoogle Scholar
- Ohata K, Ichikawa T, Nakao K, Shigeno M, Nishimura D, Ishikawa H, Hamasaki K, Eguchi K: Interferon alpha inhibits the nuclear factor kappa B activation triggered by X gene product of hepatitis B virus in human hepatoma cells. FEBS Lett. 2003, 553: 304-308. 10.1016/S0014-5793(03)01034-2.View ArticlePubMedGoogle Scholar
- Alexopoulou L, Holt A, Medzhitov R, Flavell R: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001, 413: 732-738. 10.1038/35099560.View ArticlePubMedGoogle Scholar
- Manna S, Mukhopadhyay A, Aggarwal B: IFN-alpha suppresses activation of nuclear transcription factors NF-kappa B and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol. 2000, 165: 4927-4934.View ArticlePubMedGoogle Scholar
- Bassères D, Baldwin A: Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006, 25: 6817-6830. 10.1038/sj.onc.1209942.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.